| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
|
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding oral administration of aminolevulinic acid during lactation. To minimize infant exposure, breastfeeding can be suspended for 24 hours after oral administration. Due to extremely low systemic absorption, breastfeeding is not expected to result in infant exposure to topically applied aminolevulinic acid. Aminolevulinic acid-induced photodynamic therapy has been successfully used to treat various nipple skin lesions. This therapy appears to help maintain nipple anatomy, thus facilitating breastfeeding. ◉ Effects on Breastfed Infants No relevant published information was found as of the revision date. ◉ Effects on Lactation and Breast Milk No relevant published information was found as of the revision date. |
| References |
|
| Additional Infomation |
5-Aminolevulinic acid salt is the monohydrochloride salt of 5-aminolevulinic acid. It is metabolized to protoporphyrin IX, a photosensitizing compound that accumulates in the skin. It is used in conjunction with blue light irradiation to treat mild to moderate actinic keratosis of the face or scalp. It has a dual role as an antitumor drug, photosensitizer, dermatological drug, and prodrug. It contains 5-aminolevulinic acid.
Aminolevulinic acid salt is the hydrochloride form of aminolevulinic acid (an aminoketone) used for topical photosensitization therapy. Aminolevulinic acid (ALA) is a metabolic prodrug that can be converted into the photosensitizer protoporphyrin IX (PpIX), which accumulates intracellularly. When exposed to light of an appropriate wavelength (red or blue), PpIX catalyzes the production of singlet oxygen, an endotoxin that can further react to generate superoxide anions and hydroxyl radicals. This leads to cytotoxic effects. PpIX is an intermediate compound produced from succinyl-CoA and glycine during heme synthesis. It is used as a photochemotherapy for actinic keratosis. See also: Aminolevulinic acid (with active fraction). Drug Indications Gliolan is indicated for adult patients for visualization of malignant tissue during surgery for malignant gliomas (WHO grades III and IV). For the treatment of mild to moderate actinic keratosis (Olsen grades 1 to 2; see Section 5.1) and carcinomatous fields of the face and scalp in adults. It may be used as a treatment for superficial and/or nodular basal cell carcinoma in adults who are unsuitable for surgical treatment due to treatment-related complications and/or poor cosmetic outcomes. |
| Molecular Formula |
C5H10CL15NO3
|
|---|---|
| Molecular Weight |
168.58
|
| Exact Mass |
168.032
|
| CAS # |
116571-80-3
|
| Related CAS # |
5-Aminolevulinic acid hydrochloride;5451-09-2
|
| PubChem CID |
123608
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.881
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
121
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(=O)(C[15NH2])CCC(=O)O.Cl
|
| InChi Key |
ZLHFONARZHCSET-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
|
| Chemical Name |
5-amino-4-oxopentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9319 mL | 29.6595 mL | 59.3190 mL | |
| 5 mM | 1.1864 mL | 5.9319 mL | 11.8638 mL | |
| 10 mM | 0.5932 mL | 2.9660 mL | 5.9319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
